Margaret Gatti-Mays, MD MPH
@drgattimays.bsky.social
Deputy Director Ohio State #MedicalOncology and #BreastCancer Section Chief @OSUCCCjames |#immunotherapy | #Medsky #OncSky #BoyMom | #NIH alumnus | #HoyaSaxa | Posts -My Own
Pinned
Looking for your first faculty position? Or perhaps new start? THE Ohio State University Comprehensive Cancer Center (Columbus, OH) is hiring in several #MedOnc sections - GI, Thoracic, Breast, Neuroendocrine, cutaneous. #AcademicJobs #OSUCCC @osucccjames.bsky.social @christianrolfo.bsky.social
🧐 A 75yo ♀️w/ ER+/HER2- PIK3CA+ mBC is starting 2L therapy with alpelisib + fulvestrant. Baseline A1C is 6.1 and BMI is 33. What steps can limit risk for severe hyperglycemia❓
October 22, 2025 at 1:06 AM
🧐 A 75yo ♀️w/ ER+/HER2- PIK3CA+ mBC is starting 2L therapy with alpelisib + fulvestrant. Baseline A1C is 6.1 and BMI is 33. What steps can limit risk for severe hyperglycemia❓
#PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval 🔗 integrityce.com/TBTeval24
👉🏽ALL CME🔗 integrityce.com/TBT2024
👉🏽#CME Eval 🔗 integrityce.com/TBTeval24
👉🏽ALL CME🔗 integrityce.com/TBT2024
2024 Tumor Board Tuesday Evaluation
Take this survey powered by surveymonkey.com. Create your own surveys for free.
integrityce.com
October 22, 2025 at 12:58 AM
#PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval 🔗 integrityce.com/TBTeval24
👉🏽ALL CME🔗 integrityce.com/TBT2024
👉🏽#CME Eval 🔗 integrityce.com/TBTeval24
👉🏽ALL CME🔗 integrityce.com/TBT2024
18/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 12🏫
🔊Take home points 🔊:
✅ Liquid biopsy recommended at progression on 1L to screen for mutations
✅ 2L options have mPFS 5-11 months, some with OS benefit
✅ Optimal sequence unknown at this time, likely depends in part on patient factors
👩🏻🏫Mini Tweetorial 12🏫
🔊Take home points 🔊:
✅ Liquid biopsy recommended at progression on 1L to screen for mutations
✅ 2L options have mPFS 5-11 months, some with OS benefit
✅ Optimal sequence unknown at this time, likely depends in part on patient factors
October 22, 2025 at 12:56 AM
18/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 12🏫
🔊Take home points 🔊:
✅ Liquid biopsy recommended at progression on 1L to screen for mutations
✅ 2L options have mPFS 5-11 months, some with OS benefit
✅ Optimal sequence unknown at this time, likely depends in part on patient factors
👩🏻🏫Mini Tweetorial 12🏫
🔊Take home points 🔊:
✅ Liquid biopsy recommended at progression on 1L to screen for mutations
✅ 2L options have mPFS 5-11 months, some with OS benefit
✅ Optimal sequence unknown at this time, likely depends in part on patient factors
17/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 11🏫
Ongoing trials in the HR+/HER2- space…
1️⃣ HERTHENA-Breast04 (NCT07060807)
💊 Patritumab deruxtecan (HER3-DXd) vs physician’s choice chemo
💉 ADC of HER3 mAb linked to topoisomerase I payload
👆Primary endpoints: PFS and OS
👩🏻🏫Mini Tweetorial 11🏫
Ongoing trials in the HR+/HER2- space…
1️⃣ HERTHENA-Breast04 (NCT07060807)
💊 Patritumab deruxtecan (HER3-DXd) vs physician’s choice chemo
💉 ADC of HER3 mAb linked to topoisomerase I payload
👆Primary endpoints: PFS and OS
October 22, 2025 at 12:48 AM
17/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 11🏫
Ongoing trials in the HR+/HER2- space…
1️⃣ HERTHENA-Breast04 (NCT07060807)
💊 Patritumab deruxtecan (HER3-DXd) vs physician’s choice chemo
💉 ADC of HER3 mAb linked to topoisomerase I payload
👆Primary endpoints: PFS and OS
👩🏻🏫Mini Tweetorial 11🏫
Ongoing trials in the HR+/HER2- space…
1️⃣ HERTHENA-Breast04 (NCT07060807)
💊 Patritumab deruxtecan (HER3-DXd) vs physician’s choice chemo
💉 ADC of HER3 mAb linked to topoisomerase I payload
👆Primary endpoints: PFS and OS
16/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 10🏫
DESTINY-Breast04
👩🦳 2L metastatic HER2- low BC
✅ Included both ER+ and ER-; HER2-low breakdown: IHC1+ = 58% and IHC2+ = 42%
💊 Trastuzumab deruxtecan (T-DXd) vs physician’s choice chemo (capecitabine, eribulin, gemcitabine, paclitaxel or nab-paclitaxel)
👩🏻🏫Mini Tweetorial 10🏫
DESTINY-Breast04
👩🦳 2L metastatic HER2- low BC
✅ Included both ER+ and ER-; HER2-low breakdown: IHC1+ = 58% and IHC2+ = 42%
💊 Trastuzumab deruxtecan (T-DXd) vs physician’s choice chemo (capecitabine, eribulin, gemcitabine, paclitaxel or nab-paclitaxel)
October 22, 2025 at 12:45 AM
16/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 10🏫
DESTINY-Breast04
👩🦳 2L metastatic HER2- low BC
✅ Included both ER+ and ER-; HER2-low breakdown: IHC1+ = 58% and IHC2+ = 42%
💊 Trastuzumab deruxtecan (T-DXd) vs physician’s choice chemo (capecitabine, eribulin, gemcitabine, paclitaxel or nab-paclitaxel)
👩🏻🏫Mini Tweetorial 10🏫
DESTINY-Breast04
👩🦳 2L metastatic HER2- low BC
✅ Included both ER+ and ER-; HER2-low breakdown: IHC1+ = 58% and IHC2+ = 42%
💊 Trastuzumab deruxtecan (T-DXd) vs physician’s choice chemo (capecitabine, eribulin, gemcitabine, paclitaxel or nab-paclitaxel)
15/18 #TumorBoardTuesday
⏭️ Moving on to Case 3…
#TumorBoardTuesday #OncTwitter Case 3
👩🦳 67 y.o. postmenopausal female
💉 Metastatic HR+, “HER2 low” BC to bone, liver
💊 Progressed on 1L CDK4/6i + ET within 4 months of starting therapy
🧪 No BRCA mutations
⏭️ Moving on to Case 3…
#TumorBoardTuesday #OncTwitter Case 3
👩🦳 67 y.o. postmenopausal female
💉 Metastatic HR+, “HER2 low” BC to bone, liver
💊 Progressed on 1L CDK4/6i + ET within 4 months of starting therapy
🧪 No BRCA mutations
October 22, 2025 at 12:43 AM
15/18 #TumorBoardTuesday
⏭️ Moving on to Case 3…
#TumorBoardTuesday #OncTwitter Case 3
👩🦳 67 y.o. postmenopausal female
💉 Metastatic HR+, “HER2 low” BC to bone, liver
💊 Progressed on 1L CDK4/6i + ET within 4 months of starting therapy
🧪 No BRCA mutations
⏭️ Moving on to Case 3…
#TumorBoardTuesday #OncTwitter Case 3
👩🦳 67 y.o. postmenopausal female
💉 Metastatic HR+, “HER2 low” BC to bone, liver
💊 Progressed on 1L CDK4/6i + ET within 4 months of starting therapy
🧪 No BRCA mutations
14/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 9🏫
📰 Breaking news! 🔊 evERA study (#ESMO2025)
🔎 Phase III, randomized trial (NCT05306340)
👩🦳 Metastatic HR+/HER2-
✅ Previous tx w/ CDK4/6i + ET
💊 Giredestrant is a novel, nonsteroidal oral SERD 🚫 NOT FDA approved as of today
👩🏻🏫Mini Tweetorial 9🏫
📰 Breaking news! 🔊 evERA study (#ESMO2025)
🔎 Phase III, randomized trial (NCT05306340)
👩🦳 Metastatic HR+/HER2-
✅ Previous tx w/ CDK4/6i + ET
💊 Giredestrant is a novel, nonsteroidal oral SERD 🚫 NOT FDA approved as of today
October 22, 2025 at 12:41 AM
14/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 9🏫
📰 Breaking news! 🔊 evERA study (#ESMO2025)
🔎 Phase III, randomized trial (NCT05306340)
👩🦳 Metastatic HR+/HER2-
✅ Previous tx w/ CDK4/6i + ET
💊 Giredestrant is a novel, nonsteroidal oral SERD 🚫 NOT FDA approved as of today
👩🏻🏫Mini Tweetorial 9🏫
📰 Breaking news! 🔊 evERA study (#ESMO2025)
🔎 Phase III, randomized trial (NCT05306340)
👩🦳 Metastatic HR+/HER2-
✅ Previous tx w/ CDK4/6i + ET
💊 Giredestrant is a novel, nonsteroidal oral SERD 🚫 NOT FDA approved as of today
13/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 8🏫
PrE0102: An oldie but goodie
👩🦳 2L mBC AI-resistant, HR+/HER2-
✅ Prior ET, < 1 chemo
💉 Fulvestrant + Everolimus (mTOR inh) vs Fulvestrant
⬆️ mPFS 10.3 months fulvestrant + everolimus vs 5.1 fulvestrant
👄 Mucositis → steroid mouth rinse (SWISH study ppx)
👩🏻🏫Mini Tweetorial 8🏫
PrE0102: An oldie but goodie
👩🦳 2L mBC AI-resistant, HR+/HER2-
✅ Prior ET, < 1 chemo
💉 Fulvestrant + Everolimus (mTOR inh) vs Fulvestrant
⬆️ mPFS 10.3 months fulvestrant + everolimus vs 5.1 fulvestrant
👄 Mucositis → steroid mouth rinse (SWISH study ppx)
October 22, 2025 at 12:39 AM
13/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 8🏫
PrE0102: An oldie but goodie
👩🦳 2L mBC AI-resistant, HR+/HER2-
✅ Prior ET, < 1 chemo
💉 Fulvestrant + Everolimus (mTOR inh) vs Fulvestrant
⬆️ mPFS 10.3 months fulvestrant + everolimus vs 5.1 fulvestrant
👄 Mucositis → steroid mouth rinse (SWISH study ppx)
👩🏻🏫Mini Tweetorial 8🏫
PrE0102: An oldie but goodie
👩🦳 2L mBC AI-resistant, HR+/HER2-
✅ Prior ET, < 1 chemo
💉 Fulvestrant + Everolimus (mTOR inh) vs Fulvestrant
⬆️ mPFS 10.3 months fulvestrant + everolimus vs 5.1 fulvestrant
👄 Mucositis → steroid mouth rinse (SWISH study ppx)
12/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 7🏫
EMBER-3
👩🦳 2L mHR+/HER2- 💊 Imlunestrant, next gen oral SERD with 🧠CNS activity
✅ 1-2 prior ET +/- CDK4/6i [recurrence < 12 mon or adj CDK4/6i/AI or PD on 1L CDK4/6i/ET]
📝 💊 Imlunestrant daily vs SOC [fulvestrant or exemestane] vs Imlunestrant + Abema
👩🏻🏫Mini Tweetorial 7🏫
EMBER-3
👩🦳 2L mHR+/HER2- 💊 Imlunestrant, next gen oral SERD with 🧠CNS activity
✅ 1-2 prior ET +/- CDK4/6i [recurrence < 12 mon or adj CDK4/6i/AI or PD on 1L CDK4/6i/ET]
📝 💊 Imlunestrant daily vs SOC [fulvestrant or exemestane] vs Imlunestrant + Abema
October 22, 2025 at 12:37 AM
12/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 7🏫
EMBER-3
👩🦳 2L mHR+/HER2- 💊 Imlunestrant, next gen oral SERD with 🧠CNS activity
✅ 1-2 prior ET +/- CDK4/6i [recurrence < 12 mon or adj CDK4/6i/AI or PD on 1L CDK4/6i/ET]
📝 💊 Imlunestrant daily vs SOC [fulvestrant or exemestane] vs Imlunestrant + Abema
👩🏻🏫Mini Tweetorial 7🏫
EMBER-3
👩🦳 2L mHR+/HER2- 💊 Imlunestrant, next gen oral SERD with 🧠CNS activity
✅ 1-2 prior ET +/- CDK4/6i [recurrence < 12 mon or adj CDK4/6i/AI or PD on 1L CDK4/6i/ET]
📝 💊 Imlunestrant daily vs SOC [fulvestrant or exemestane] vs Imlunestrant + Abema
11/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 6🏫
EMERALD
👩🦳 2L mHR+/HER2- Elacestrant, po SERD
✅ 1-2 prior ET incl CDK4/6i, < 1 chemo
💊 Elacestrant daily vs 💉fulvestrant or AI
⬆️PFS for prior CDK4/6i >12 mon + ESR1mut
⬆️ PFS all subgroups incl 🦴only, 🫁 visceral, >3 mets
👩🏻🏫Mini Tweetorial 6🏫
EMERALD
👩🦳 2L mHR+/HER2- Elacestrant, po SERD
✅ 1-2 prior ET incl CDK4/6i, < 1 chemo
💊 Elacestrant daily vs 💉fulvestrant or AI
⬆️PFS for prior CDK4/6i >12 mon + ESR1mut
⬆️ PFS all subgroups incl 🦴only, 🫁 visceral, >3 mets
October 22, 2025 at 12:35 AM
11/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 6🏫
EMERALD
👩🦳 2L mHR+/HER2- Elacestrant, po SERD
✅ 1-2 prior ET incl CDK4/6i, < 1 chemo
💊 Elacestrant daily vs 💉fulvestrant or AI
⬆️PFS for prior CDK4/6i >12 mon + ESR1mut
⬆️ PFS all subgroups incl 🦴only, 🫁 visceral, >3 mets
👩🏻🏫Mini Tweetorial 6🏫
EMERALD
👩🦳 2L mHR+/HER2- Elacestrant, po SERD
✅ 1-2 prior ET incl CDK4/6i, < 1 chemo
💊 Elacestrant daily vs 💉fulvestrant or AI
⬆️PFS for prior CDK4/6i >12 mon + ESR1mut
⬆️ PFS all subgroups incl 🦴only, 🫁 visceral, >3 mets
10/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 5🏫
🤔What is “endocrine resistant”?
Per ABC Intern'l Guidelines,
👉 Recurred while taking adj ET
👉 Recurred < 2 yrs of adj ET
👉 Progressed < 6 mons of starting 1L mBC tx
👉 Progression after 2L+ ET
👉 Known ESR1 mut [use elacestrant or imlunestrant]
👩🏻🏫Mini Tweetorial 5🏫
🤔What is “endocrine resistant”?
Per ABC Intern'l Guidelines,
👉 Recurred while taking adj ET
👉 Recurred < 2 yrs of adj ET
👉 Progressed < 6 mons of starting 1L mBC tx
👉 Progression after 2L+ ET
👉 Known ESR1 mut [use elacestrant or imlunestrant]
October 22, 2025 at 12:30 AM
10/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 5🏫
🤔What is “endocrine resistant”?
Per ABC Intern'l Guidelines,
👉 Recurred while taking adj ET
👉 Recurred < 2 yrs of adj ET
👉 Progressed < 6 mons of starting 1L mBC tx
👉 Progression after 2L+ ET
👉 Known ESR1 mut [use elacestrant or imlunestrant]
👩🏻🏫Mini Tweetorial 5🏫
🤔What is “endocrine resistant”?
Per ABC Intern'l Guidelines,
👉 Recurred while taking adj ET
👉 Recurred < 2 yrs of adj ET
👉 Progressed < 6 mons of starting 1L mBC tx
👉 Progression after 2L+ ET
👉 Known ESR1 mut [use elacestrant or imlunestrant]
9/18 #TumorBoardTuesday
⏭️ Moving on to Case 2…
#TumorBoardTuesday #OncTwitter Case 2
👩🦳 62 y.o. postmeno female
💉 mBC to the lungs, ER 70%, PR 85%, HER2 neg [IHC 1] with progression on 1L ribociclib/letrozole at C7.
🏃♀️ ECOG PS1. No co-morbidities.
⛔ Nml VS, labs
🩸Liquid Biopsy: ESR1mut, TMB-High
⏭️ Moving on to Case 2…
#TumorBoardTuesday #OncTwitter Case 2
👩🦳 62 y.o. postmeno female
💉 mBC to the lungs, ER 70%, PR 85%, HER2 neg [IHC 1] with progression on 1L ribociclib/letrozole at C7.
🏃♀️ ECOG PS1. No co-morbidities.
⛔ Nml VS, labs
🩸Liquid Biopsy: ESR1mut, TMB-High
October 22, 2025 at 12:27 AM
9/18 #TumorBoardTuesday
⏭️ Moving on to Case 2…
#TumorBoardTuesday #OncTwitter Case 2
👩🦳 62 y.o. postmeno female
💉 mBC to the lungs, ER 70%, PR 85%, HER2 neg [IHC 1] with progression on 1L ribociclib/letrozole at C7.
🏃♀️ ECOG PS1. No co-morbidities.
⛔ Nml VS, labs
🩸Liquid Biopsy: ESR1mut, TMB-High
⏭️ Moving on to Case 2…
#TumorBoardTuesday #OncTwitter Case 2
👩🦳 62 y.o. postmeno female
💉 mBC to the lungs, ER 70%, PR 85%, HER2 neg [IHC 1] with progression on 1L ribociclib/letrozole at C7.
🏃♀️ ECOG PS1. No co-morbidities.
⛔ Nml VS, labs
🩸Liquid Biopsy: ESR1mut, TMB-High
8/18 #TumorBoardTuesday
Back to our case🔎
👩🦳 Received Capi + Fulvestrant [PIK3CA mutation].
👉 Not yet endocrine resistant [not move to cape, saci]
👉 Tumor is HER2 neg [no TDxD]
👉 Not Everolimus + fulvestrant b/c more targeted approach PIK3CA
✅ Mild rash at start -> resolved with antihistamines
Back to our case🔎
👩🦳 Received Capi + Fulvestrant [PIK3CA mutation].
👉 Not yet endocrine resistant [not move to cape, saci]
👉 Tumor is HER2 neg [no TDxD]
👉 Not Everolimus + fulvestrant b/c more targeted approach PIK3CA
✅ Mild rash at start -> resolved with antihistamines
October 22, 2025 at 12:26 AM
8/18 #TumorBoardTuesday
Back to our case🔎
👩🦳 Received Capi + Fulvestrant [PIK3CA mutation].
👉 Not yet endocrine resistant [not move to cape, saci]
👉 Tumor is HER2 neg [no TDxD]
👉 Not Everolimus + fulvestrant b/c more targeted approach PIK3CA
✅ Mild rash at start -> resolved with antihistamines
Back to our case🔎
👩🦳 Received Capi + Fulvestrant [PIK3CA mutation].
👉 Not yet endocrine resistant [not move to cape, saci]
👉 Tumor is HER2 neg [no TDxD]
👉 Not Everolimus + fulvestrant b/c more targeted approach PIK3CA
✅ Mild rash at start -> resolved with antihistamines
7/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 4🏫
💊Approved PIK3CA-inh: Capivasertib or Alpelisib or Inalvosalib
🤔 How do you PIK?
☝️Inavolisib + Fulvestrant + Palbo-> 1st line mER+ BC s/p recurrence on/after adj ET
✌️Both Alpelisib, Capi approved in 2nd line mER+ BC + fulvestrant
🔎 NGS, Baseline A1C
👩🏻🏫Mini Tweetorial 4🏫
💊Approved PIK3CA-inh: Capivasertib or Alpelisib or Inalvosalib
🤔 How do you PIK?
☝️Inavolisib + Fulvestrant + Palbo-> 1st line mER+ BC s/p recurrence on/after adj ET
✌️Both Alpelisib, Capi approved in 2nd line mER+ BC + fulvestrant
🔎 NGS, Baseline A1C
October 22, 2025 at 12:20 AM
7/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 4🏫
💊Approved PIK3CA-inh: Capivasertib or Alpelisib or Inalvosalib
🤔 How do you PIK?
☝️Inavolisib + Fulvestrant + Palbo-> 1st line mER+ BC s/p recurrence on/after adj ET
✌️Both Alpelisib, Capi approved in 2nd line mER+ BC + fulvestrant
🔎 NGS, Baseline A1C
👩🏻🏫Mini Tweetorial 4🏫
💊Approved PIK3CA-inh: Capivasertib or Alpelisib or Inalvosalib
🤔 How do you PIK?
☝️Inavolisib + Fulvestrant + Palbo-> 1st line mER+ BC s/p recurrence on/after adj ET
✌️Both Alpelisib, Capi approved in 2nd line mER+ BC + fulvestrant
🔎 NGS, Baseline A1C
5/18 #TumorBoardTuesday
Back to our case🔎
💉 57yo ♀️ mBC to the bones, liver, ER100%, PR95%, HER2 neg [IHC 0] with progression on 1L ribociclib/letrozole at C47
✅ Normal labs (A1C = 5.8), VS
🩸Liquid Biopsy: +PIK3CA mut, TP53 mut, TMB-Low, tumor fraction (> 5%)
👩🏻⚕️ Recommend 2L therapy next…
Back to our case🔎
💉 57yo ♀️ mBC to the bones, liver, ER100%, PR95%, HER2 neg [IHC 0] with progression on 1L ribociclib/letrozole at C47
✅ Normal labs (A1C = 5.8), VS
🩸Liquid Biopsy: +PIK3CA mut, TP53 mut, TMB-Low, tumor fraction (> 5%)
👩🏻⚕️ Recommend 2L therapy next…
October 22, 2025 at 12:17 AM
5/18 #TumorBoardTuesday
Back to our case🔎
💉 57yo ♀️ mBC to the bones, liver, ER100%, PR95%, HER2 neg [IHC 0] with progression on 1L ribociclib/letrozole at C47
✅ Normal labs (A1C = 5.8), VS
🩸Liquid Biopsy: +PIK3CA mut, TP53 mut, TMB-Low, tumor fraction (> 5%)
👩🏻⚕️ Recommend 2L therapy next…
Back to our case🔎
💉 57yo ♀️ mBC to the bones, liver, ER100%, PR95%, HER2 neg [IHC 0] with progression on 1L ribociclib/letrozole at C47
✅ Normal labs (A1C = 5.8), VS
🩸Liquid Biopsy: +PIK3CA mut, TP53 mut, TMB-Low, tumor fraction (> 5%)
👩🏻⚕️ Recommend 2L therapy next…
4/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 3🏫
CAPItello-291: Capi Side effects
💊 Capi: 4 days on, 3 days off per week
🩺 Baseline A1C < 8%
🚽 Common AE: Diarrhea day 8 [All grades 72%, G3/4 9.3%]
☝️ Rash (12%) ~ day 12→ oral antihistamine, topical steroids
💉 Hyperglycemia (18%)~ day 15; ⬇️ G3/G4
👩🏻🏫Mini Tweetorial 3🏫
CAPItello-291: Capi Side effects
💊 Capi: 4 days on, 3 days off per week
🩺 Baseline A1C < 8%
🚽 Common AE: Diarrhea day 8 [All grades 72%, G3/4 9.3%]
☝️ Rash (12%) ~ day 12→ oral antihistamine, topical steroids
💉 Hyperglycemia (18%)~ day 15; ⬇️ G3/G4
October 22, 2025 at 12:12 AM
4/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 3🏫
CAPItello-291: Capi Side effects
💊 Capi: 4 days on, 3 days off per week
🩺 Baseline A1C < 8%
🚽 Common AE: Diarrhea day 8 [All grades 72%, G3/4 9.3%]
☝️ Rash (12%) ~ day 12→ oral antihistamine, topical steroids
💉 Hyperglycemia (18%)~ day 15; ⬇️ G3/G4
👩🏻🏫Mini Tweetorial 3🏫
CAPItello-291: Capi Side effects
💊 Capi: 4 days on, 3 days off per week
🩺 Baseline A1C < 8%
🚽 Common AE: Diarrhea day 8 [All grades 72%, G3/4 9.3%]
☝️ Rash (12%) ~ day 12→ oral antihistamine, topical steroids
💉 Hyperglycemia (18%)~ day 15; ⬇️ G3/G4
3/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 2🏫
CAPItello291
👩🦳 mER+/HER2- BC, PD on AI+/-CDK4/6i
💉2L Fulvestrant +/- capi [🚫AKT plus 🚫PTEN, 🚫PIK3CA]
✅ Capi + fulvestrant ⬆️mPFS in AKT alterations [7.3m vs 3.1m]
✅ Capi+Fulvestrant benefited all incl 🦴only, 🫁 visceral mets, prior CDK4/6i, prior ☣️chemo
👩🏻🏫Mini Tweetorial 2🏫
CAPItello291
👩🦳 mER+/HER2- BC, PD on AI+/-CDK4/6i
💉2L Fulvestrant +/- capi [🚫AKT plus 🚫PTEN, 🚫PIK3CA]
✅ Capi + fulvestrant ⬆️mPFS in AKT alterations [7.3m vs 3.1m]
✅ Capi+Fulvestrant benefited all incl 🦴only, 🫁 visceral mets, prior CDK4/6i, prior ☣️chemo
October 22, 2025 at 12:08 AM
3/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 2🏫
CAPItello291
👩🦳 mER+/HER2- BC, PD on AI+/-CDK4/6i
💉2L Fulvestrant +/- capi [🚫AKT plus 🚫PTEN, 🚫PIK3CA]
✅ Capi + fulvestrant ⬆️mPFS in AKT alterations [7.3m vs 3.1m]
✅ Capi+Fulvestrant benefited all incl 🦴only, 🫁 visceral mets, prior CDK4/6i, prior ☣️chemo
👩🏻🏫Mini Tweetorial 2🏫
CAPItello291
👩🦳 mER+/HER2- BC, PD on AI+/-CDK4/6i
💉2L Fulvestrant +/- capi [🚫AKT plus 🚫PTEN, 🚫PIK3CA]
✅ Capi + fulvestrant ⬆️mPFS in AKT alterations [7.3m vs 3.1m]
✅ Capi+Fulvestrant benefited all incl 🦴only, 🫁 visceral mets, prior CDK4/6i, prior ☣️chemo
POLL
What would you do next?
A) Start capecitabine
B) Liquid biopsy
C) Start trastuzumab deruxtecan
D) Check tumor markers Ca 15-3, Ca 27.29
@christianrolfo.bsky.social @quirogad.bsky.social @nerealliamd.bsky.social @stoverlab.bsky.social @drsgraff.bsky.social @oncbrothers.bsky.social
What would you do next?
A) Start capecitabine
B) Liquid biopsy
C) Start trastuzumab deruxtecan
D) Check tumor markers Ca 15-3, Ca 27.29
@christianrolfo.bsky.social @quirogad.bsky.social @nerealliamd.bsky.social @stoverlab.bsky.social @drsgraff.bsky.social @oncbrothers.bsky.social
October 22, 2025 at 12:03 AM
POLL
What would you do next?
A) Start capecitabine
B) Liquid biopsy
C) Start trastuzumab deruxtecan
D) Check tumor markers Ca 15-3, Ca 27.29
@christianrolfo.bsky.social @quirogad.bsky.social @nerealliamd.bsky.social @stoverlab.bsky.social @drsgraff.bsky.social @oncbrothers.bsky.social
What would you do next?
A) Start capecitabine
B) Liquid biopsy
C) Start trastuzumab deruxtecan
D) Check tumor markers Ca 15-3, Ca 27.29
@christianrolfo.bsky.social @quirogad.bsky.social @nerealliamd.bsky.social @stoverlab.bsky.social @drsgraff.bsky.social @oncbrothers.bsky.social
1/18 #TumorBoardTuesday #OncTwitter Case 1
👩🦳 57 y.o. postmenopausal female
📋 Well controlled diabetes (A1C = 5.8)
🏃♀️ ECOG PS 0
💉 Metastatic breast cancer to the bones, liver, ER100%, PR95%, HER2 neg [IHC 0] with scan confirmed progression on 1L ribociclib/letrozole Cyc 47 in bones.
⛔ Normal labs,VS
👩🦳 57 y.o. postmenopausal female
📋 Well controlled diabetes (A1C = 5.8)
🏃♀️ ECOG PS 0
💉 Metastatic breast cancer to the bones, liver, ER100%, PR95%, HER2 neg [IHC 0] with scan confirmed progression on 1L ribociclib/letrozole Cyc 47 in bones.
⛔ Normal labs,VS
October 22, 2025 at 12:01 AM
1/18 #TumorBoardTuesday #OncTwitter Case 1
👩🦳 57 y.o. postmenopausal female
📋 Well controlled diabetes (A1C = 5.8)
🏃♀️ ECOG PS 0
💉 Metastatic breast cancer to the bones, liver, ER100%, PR95%, HER2 neg [IHC 0] with scan confirmed progression on 1L ribociclib/letrozole Cyc 47 in bones.
⛔ Normal labs,VS
👩🦳 57 y.o. postmenopausal female
📋 Well controlled diabetes (A1C = 5.8)
🏃♀️ ECOG PS 0
💉 Metastatic breast cancer to the bones, liver, ER100%, PR95%, HER2 neg [IHC 0] with scan confirmed progression on 1L ribociclib/letrozole Cyc 47 in bones.
⛔ Normal labs,VS
Tune in tomorrow 10/21/25 at 8pm EST for discussion about the ever changing landscape of 2L metastatic ER+ breast cancer #TBT #BCSM @tumorboardtuesday.bsky.social @osuwexmed.bsky.social #BreastCancer
🎙️Looking forward to a great #TBT discussion on Oct 21, 2025 on 2L ER+/HER2- #metastaticbreast cancer #BCSM @osuwexmed.bsky.social
October 21, 2025 at 1:06 AM
Tune in tomorrow 10/21/25 at 8pm EST for discussion about the ever changing landscape of 2L metastatic ER+ breast cancer #TBT #BCSM @tumorboardtuesday.bsky.social @osuwexmed.bsky.social #BreastCancer
🎙️Looking forward to a great #TBT discussion on Oct 21, 2025 on 2L ER+/HER2- #metastaticbreast cancer #BCSM @osuwexmed.bsky.social
October 17, 2025 at 12:17 AM
🎙️Looking forward to a great #TBT discussion on Oct 21, 2025 on 2L ER+/HER2- #metastaticbreast cancer #BCSM @osuwexmed.bsky.social
Excited to share my #Top5 in #breastcancer from #ASCO25 #bcsm @osuwexmed.bsky.social
www.vumedi.com/video/ascor-...
www.vumedi.com/video/ascor-...
ASCO® 2025 Highlights: Key Trial Updates Across Breast Cancer Subtypes - ADCs, Chemo De-Escalation, CDK4/6i, IO Combinations, and Oral SERDs
A video from Margaret Gatti-Mays (as part of 2025 ASCO® Annual Meeting Insights Hub), posted on Aug 27, 2025.
www.vumedi.com
August 30, 2025 at 12:07 PM
Excited to share my #Top5 in #breastcancer from #ASCO25 #bcsm @osuwexmed.bsky.social
www.vumedi.com/video/ascor-...
www.vumedi.com/video/ascor-...
Last training ride before #pelotonia25. Since May, I’ve spent 30 hours and traveled more than 360 miles so that next Saturday I will ride 50 miles with more than 7,000 of my closest friends to help support #CancerResearch #onegoal #LetsDoThis #FuelMyRide ➡️ www.pelotonia.org/profile/MG0328
July 27, 2025 at 4:41 PM
Last training ride before #pelotonia25. Since May, I’ve spent 30 hours and traveled more than 360 miles so that next Saturday I will ride 50 miles with more than 7,000 of my closest friends to help support #CancerResearch #onegoal #LetsDoThis #FuelMyRide ➡️ www.pelotonia.org/profile/MG0328
@oncoalert.bsky.social annual #ASCO25 5K on a beautiful morning in Chicago! Had some great running partners this am @quirogad.bsky.social @christeeny513.bsky.social
May 31, 2025 at 12:58 PM
@oncoalert.bsky.social annual #ASCO25 5K on a beautiful morning in Chicago! Had some great running partners this am @quirogad.bsky.social @christeeny513.bsky.social
#ASCO25 has started! Great catching up with @drsgraff.bsky.social and Dr Gao!
May 31, 2025 at 1:00 AM
#ASCO25 has started! Great catching up with @drsgraff.bsky.social and Dr Gao!